Myrbetriq approved for overactive bladder

(HealthDay) -- Myrbetriq (mirabegron) has been approved to treat adults with overactive bladder, a condition affecting some 33 million Americans, the U.S. Food and Drug Administration said Thursday in a news release.

The drug is designed to relax the as the bladder fills, minimizing the potential symptoms of needing to urinate too often, needing to urinate immediately or the involuntary leakage of urine, the agency said.

The drug's safety and effectiveness were evaluated in clinical studies involving 4,116 people with overactive bladder. The most common side effects were a rise in blood pressure, cold-like symptoms, urinary tract infection, constipation, fatigue, increased heart rate and abdominal pain.

Myrbetriq is marketed by Astellas Pharma US, based in Northbrook, Ill.


Explore further

Bladder 'pacemaker' can fix overactive bladder, other voiding issues

More information: The U.S. National Library of Medicine has more about overactive bladder.

Copyright © 2012 HealthDay. All rights reserved.

Citation: Myrbetriq approved for overactive bladder (2012, June 28) retrieved 27 November 2021 from https://medicalxpress.com/news/2012-06-myrbetriq-overactive-bladder.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors